ChiCTR2100052260 版本V1.0 版本创建时间2022/04/24 12:57:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052260 

最近更新日期:

Date of Last Refreshed on:

2021-10-24 00:27:59 

注册时间:

Date of Registration:

2021-10-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

老年导尿管相关泌尿系感染精准治疗

Public title:

Research on targeted treatment of urinary tract infection associated with catheter in the elderly patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年导尿管相关泌尿系感染精准治疗

Scientific title:

Research on targeted treatment of urinary tract infection associated with catheter in the elderly patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙志宏 

研究负责人:

张桂芝 

Applicant:

Sun zhihong 

Study leader:

Zhang guizhi 

申请注册联系人电话:

Applicant telephone:

15801469109

研究负责人电话:

Study leader's telephone:

18601048015

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

szh1790505@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhanggz7769@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市复兴路28号,100853

研究负责人通讯地址:

北京市复兴路28号,100853

Applicant address:

No. 28 Fuxing Road, Beijing 100853, China

Study leader's address:

No. 28 Fuxing Road, Beijing 100853, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

解放军总医院第二医学中心/国家老年医学中心呼吸与危重症医学科

Applicant's institution:

Department of Respiratory and Critical Care Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

S2021-402-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院医学伦理委员会

Name of the ethic committee:

Ethics Cpmmittee Of Chinese PLA General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-07-29 00:00:00

伦理委员会联系人:

曹江

Contact Name of the ethic committee:

Cao jiang

伦理委员会联系地址:

北京市复兴路28号,100853

Contact Address of the ethic committee:

No. 28 Fuxing Road, Beijing 100853, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-66937166

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军总医院

Primary sponsor:

Chinese PLA General Hospital

研究实施负责(组长)单位地址:

北京市复兴路28号,100853

Primary sponsor's address:

No. 28 Fuxing Road, Beijing 100853, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院

具体地址:

复兴路28号

Institution
hospital:

Chinese PLA General Hospital

Address:

28 Fuxing Road

经费或物资来源:

国家重点研发计划

Source(s) of funding:

National Key research and development program

Target disease:

urinary tract infection associated with catheter

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

提出老年导尿管相关尿路感染的精准治疗方案。  

Objectives of Study:

To propose an accurate treatment plan for urinary tract infection associated with urinary catheter in the elderly.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、年龄≥60 岁
2、符合导尿管相关尿路感染者(含膀胱造瘘)
导尿管相关尿路感染诊断标准:主要是指患者留置导尿管后,或者拔除导尿
管 48 小时内发生的泌尿系统感染。
临床诊断:患者出现尿频、尿急、尿痛等尿路刺激症状,或者有下腹触痛、
肾区叩痛,伴有或不伴有发热。
病原学诊断:在临床诊断的基础上,符合以下条件之一:
①清洁中段尿或者导尿留取尿液(非留置导尿)培养革兰阳性球菌菌落数≥
104
cfu/ml,革兰阴性杆菌菌落数≥105
cfu/ml。
②耻骨联合上膀胱穿刺留取尿液培养的细菌菌落数≥103
cfu/ml。
③新鲜尿液标本经离心应用相差显微镜检查,在每 30 个视野中有半数视野见
到细菌。
④经手术、病理学或者影像学检查,有尿路感染证据的。

Inclusion criteria

1. Age ≥60 years old.
2, in line with catheter-related urinary tract infection (including cystostomy).
Diagnostic criteria of catheter-related urinary tract infection: mainly refers to the patients after indwelling catheter, or pulling out catheter.
Urinary system infection occurred within 48 hours.
Clinical diagnosis: the patient has urinary tract irritation symptoms such as frequent micturition, urgent micturition and dysuria, or has lower abdominal tenderness.
Pain in the kidney with or without fever.
Etiological diagnosis: on the basis of clinical diagnosis, one of the following conditions is met:
①clean the urine in the middle section or retain the urine through catheterization (without indwelling catheterization) and culture the colony number of gram-positive cocci ≥104cfu/ml, and the colony number of gram-negative bacilli ≥105cfu/ml.
② The bacterial colony number of urine collected by bladder puncture above pubic symphysis was ≥103cfu/ml.
③ Fresh urine samples were centrifuged and examined by phase contrast microscope, and bacteria were found in half of every 30 visual fields.
④ After operation, pathology or imaging examination, there is evidence of urinary tract infection.

排除标准:

1、相关资料不全或研究期间死亡者
2、拒绝签署知情同意书

Exclusion criteria:

1. the relevant information is incomplete or died during the study.
2. Refuse to sign the informed consent form.

研究实施时间:

Study execute time:

From 2021-10-10 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-10 00:00:00 To 2023-06-30 00:00:00  

干预措施:

Interventions:

组别:

连续入组

样本量:

282

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

中国人民解放军总医院 

单位级别:

三甲 

Institution
hospital:

Chinese PLA General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

尿常规

指标类型:

主要指标

Outcome:

Urine routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿培养

指标类型:

主要指标

Outcome:

Urine culture

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿微流控芯片

指标类型:

主要指标

Outcome:

Urinary microfluidic chip

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血生化检测

指标类型:

次要指标

Outcome:

Blood biochemical test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血沉

指标类型:

次要指标

Outcome:

Blood sedimentation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

真菌D葡聚糖

指标类型:

次要指标

Outcome:

Fungal D-glucan

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机专员采用随机信封分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Random specialists use random envelopes to group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024.1.1后 http://www.medresman.org/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After 2024.1.1 available at http://www.medresman.org/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例记录表(Case Record Form, CRF),电子采集和管理系统使用ResMan。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

use CRF and ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-24 00:27:59